Squamous cell carcinoma treatment varies by stage, involving surgery, radiation, and systemic therapies based on cancer progression and patient health. Stage 1 focuses on tumor removal, Stage 2 ...

Camrelizumab plus chemotherapy doubled the five-year survival rate in advanced squamous lung cancer to 27.8%, reducing mortality risk by 43%. The CameL-sq trial demonstrated camrelizumab's efficacy as ...

PD-1 inhibitors versus PD-L1 inhibitors in PD-L1–negative advanced non-small cell lung cancer: A meta-analysis of survival outcomes. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting ...

Candel Therapeutics has identified a subpopulation of lung cancer patients living longest on its oncolytic virus, leading the biotech to narrow its focus as it heads towards a potentially ...

Stage 4 lung cancer life expectancy is typically gauged using five-year survival rates. These estimate the percentage of ...

This year, there was a surge of new lung cancer treatments, more options for patients with earlier-stage disease, and growing ...